These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18261583)

  • 1. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients.
    Nart A; Sipahi S; Aykas A; Uslu A; Hoşcoşkun C; Toz H
    Transplant Proc; 2008; 40(1):189-92. PubMed ID: 18261583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
    Pietruck F; Budde K; Salvadori M; Sollinger H; Bourbigot B; Gentil MA; Oppenheimer F
    Clin Transplant; 2007; 21(1):117-25. PubMed ID: 17302600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of enteric-coated mycophenolate sodium in de novo renal transplant recipients with high incidence of delayed graft function.
    Schiavelli R; Gaite L; Agost Carreno C; Baran M; Novoa P; Massari P; Otero AB; Piulats E
    Transplant Proc; 2006 Apr; 38(3):905-8. PubMed ID: 16647505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a 6-month, multicenter, open-label, prospective study concerning efficacy and safety of mycophenolate sodium in de novo kidney transplant recipients.
    Wyzgał J; Niemczyk M; Ziółkowski J; Durlik M; Wiecek A
    Transplant Proc; 2007 Nov; 39(9):2730-2. PubMed ID: 18021971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of immunosuppression by switching from azathioprine to enteric-coated mycophenolate sodium in stable kidney transplant patients.
    Gutiérrez Sánchez MJ; Morales Cerdán JM; Belmonte AA
    Transplant Proc; 2009; 41(6):2320-2. PubMed ID: 19715907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
    Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
    Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid withdrawal in kidney transplant recipients: is it a safe option?
    Sanfey H; Haussman G; Isaacs I; Ishitani M; Lobo P; McCullough C; Pruett T
    Clin Transplant; 1997 Oct; 11(5 Pt 2):500-4. PubMed ID: 9361950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
    Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
    Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients.
    Rostaing L; Mourad G; Kamar N; Garrigue V; Karras A; Lefrançois N; Charpentier B; Bourbigot B; Pouteil-Noble C; Bayle F; Lebranchu Y; Berthoux F; Le Meur Y; Kessler M; Moulin B; Ducloux D; Delahousse M; Lang P; Merville P; Chaouche-Teyara K; Legendre C;
    Transplant Proc; 2006 Nov; 38(9):2860-3. PubMed ID: 17112849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant.
    Mourad G; Karras A; Kamar N; Garrigue V; Legendre C; Lefrançois N; Charpentier B; Bourbigot B; Pouteil-Noble C; Bayle F; Lebranchu Y; Mariat C; Le Meur Y; Kessler M; Moulin B; Ducloux D; Delahousse M; Lang P; Merville P; Chaouche-Teyara K; Rostaing L;
    Clin Transplant; 2007; 21(3):295-300. PubMed ID: 17488375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
    Sharma A; Shekhar C; Heer M; Minz M
    Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin at six years can exhibit normal renal function without proteinuria or neoplasia after renal transplantation. A single-center experience.
    Nungaray N; Arriola M; Gutierrez MJ; Oliva E; Hernández E; Gonzalez E; Andres A; Morales JM
    Transplant Proc; 2005 Nov; 37(9):3727-8. PubMed ID: 16386519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
    Sollinger H
    Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M
    Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
    Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
    Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
    Kliem V; Fritsche L; Haller H; Suwelack B; Abendroth D; Fornara P; Pietruck F; Frei U; Donauer J; Lison AE; Michel U; Ulbricht B;
    Transplant Proc; 2005 Apr; 37(3):1597-600. PubMed ID: 15866683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
    Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
    Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression.
    Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G
    Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.
    Tedesco-Silva H; Mourad G; Kahan BD; Boira JG; Weimar W; Mulgaonkar S; Nashan B; Madsen S; Charpentier B; Pellet P; Vanrenterghem Y
    Transplantation; 2004 Jun; 77(12):1826-33. PubMed ID: 15223899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.